vs
AMERISAFE INC（AMSF）与MESA LABORATORIES INC（MLAB）财务数据对比。点击上方公司名可切换其他公司
AMERISAFE INC的季度营收约是MESA LABORATORIES INC的1.2倍（$80.1M vs $65.1M），AMERISAFE INC净利率更高（10.2% vs 5.6%，领先4.6%），AMERISAFE INC同比增速更快（10.3% vs 3.6%），过去两年MESA LABORATORIES INC的营收复合增速更高（5.1% vs 2.8%）
AMERISAFE Inc.是一家专业工伤保险服务商，核心经营市场为美国，覆盖本土49个州，主要为建筑、伐木、货运、制造等高风险行业的中小企业提供定制化工伤险产品及配套风险管理解决方案。
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
AMSF vs MLAB — 直观对比
营收规模更大
AMSF
是对方的1.2倍
$65.1M
营收增速更快
AMSF
高出6.7%
3.6%
净利率更高
AMSF
高出4.6%
5.6%
两年增速更快
MLAB
近两年复合增速
2.8%
损益表 — Q1 FY2026 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $80.1M | $65.1M |
| 净利润 | $8.1M | $3.6M |
| 毛利率 | — | 64.2% |
| 营业利润率 | — | 12.2% |
| 净利率 | 10.2% | 5.6% |
| 营收同比 | 10.3% | 3.6% |
| 净利润同比 | -9.0% | 316.6% |
| 每股收益（稀释后） | $0.43 | $0.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMSFMLAB
| Q1 26 | $80.1M | — | ||
| Q4 25 | $81.6M | $65.1M | ||
| Q3 25 | $82.0M | $60.7M | ||
| Q2 25 | $81.1M | $59.5M | ||
| Q1 25 | $72.6M | $62.1M | ||
| Q4 24 | $74.0M | $62.8M | ||
| Q3 24 | $78.7M | $57.8M | ||
| Q2 24 | $75.8M | $58.2M |
净利润AMSFMLAB
| Q1 26 | $8.1M | — | ||
| Q4 25 | $10.4M | $3.6M | ||
| Q3 25 | $13.8M | $2.5M | ||
| Q2 25 | $14.0M | $4.7M | ||
| Q1 25 | $8.9M | $-7.1M | ||
| Q4 24 | $13.2M | $-1.7M | ||
| Q3 24 | $14.3M | $3.4M | ||
| Q2 24 | $11.0M | $3.4M |
毛利率AMSFMLAB
| Q1 26 | — | — | ||
| Q4 25 | — | 64.2% | ||
| Q3 25 | — | 61.5% | ||
| Q2 25 | — | 62.0% | ||
| Q1 25 | — | 61.8% | ||
| Q4 24 | — | 63.3% | ||
| Q3 24 | — | 61.3% | ||
| Q2 24 | — | 64.0% |
营业利润率AMSFMLAB
| Q1 26 | — | — | ||
| Q4 25 | 15.6% | 12.2% | ||
| Q3 25 | 21.3% | 7.8% | ||
| Q2 25 | 21.5% | 5.1% | ||
| Q1 25 | 15.5% | 2.4% | ||
| Q4 24 | 22.7% | 9.2% | ||
| Q3 24 | 22.6% | 6.1% | ||
| Q2 24 | 18.1% | 9.6% |
净利率AMSFMLAB
| Q1 26 | 10.2% | — | ||
| Q4 25 | 12.8% | 5.6% | ||
| Q3 25 | 16.9% | 4.1% | ||
| Q2 25 | 17.2% | 8.0% | ||
| Q1 25 | 12.3% | -11.4% | ||
| Q4 24 | 17.8% | -2.7% | ||
| Q3 24 | 18.2% | 5.9% | ||
| Q2 24 | 14.5% | 5.8% |
每股收益（稀释后）AMSFMLAB
| Q1 26 | $0.43 | — | ||
| Q4 25 | $0.55 | $0.65 | ||
| Q3 25 | $0.72 | $0.45 | ||
| Q2 25 | $0.73 | $0.85 | ||
| Q1 25 | $0.47 | $-1.30 | ||
| Q4 24 | $0.69 | $-0.31 | ||
| Q3 24 | $0.75 | $0.63 | ||
| Q2 24 | $0.57 | $0.62 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $34.2M | $29.0M |
| 总债务越低越好 | — | $68.4M |
| 股东权益账面价值 | $246.6M | $186.7M |
| 总资产 | — | $434.8M |
| 负债/权益比越低杠杆越低 | — | 0.37× |
8季度趋势，按日历期对齐
现金及短期投资AMSFMLAB
| Q1 26 | $34.2M | — | ||
| Q4 25 | $61.9M | $29.0M | ||
| Q3 25 | $54.7M | $20.4M | ||
| Q2 25 | $48.5M | $21.3M | ||
| Q1 25 | $44.8M | $27.3M | ||
| Q4 24 | $44.1M | $27.3M | ||
| Q3 24 | $63.7M | $24.3M | ||
| Q2 24 | $30.6M | $28.5M |
总债务AMSFMLAB
| Q1 26 | — | — | ||
| Q4 25 | — | $68.4M | ||
| Q3 25 | — | $69.4M | ||
| Q2 25 | — | $70.3M | ||
| Q1 25 | — | $71.3M | ||
| Q4 24 | — | $72.2M | ||
| Q3 24 | — | $73.1M | ||
| Q2 24 | — | $74.1M |
股东权益AMSFMLAB
| Q1 26 | $246.6M | — | ||
| Q4 25 | $251.6M | $186.7M | ||
| Q3 25 | $274.8M | $178.5M | ||
| Q2 25 | $265.6M | $172.5M | ||
| Q1 25 | $260.8M | $159.8M | ||
| Q4 24 | $257.3M | $155.2M | ||
| Q3 24 | $314.4M | $161.5M | ||
| Q2 24 | $301.0M | $150.7M |
总资产AMSFMLAB
| Q1 26 | — | — | ||
| Q4 25 | $1.1B | $434.8M | ||
| Q3 25 | $1.2B | $430.4M | ||
| Q2 25 | $1.2B | $435.7M | ||
| Q1 25 | $1.2B | $433.3M | ||
| Q4 24 | $1.2B | $433.3M | ||
| Q3 24 | $1.3B | $454.1M | ||
| Q2 24 | $1.2B | $440.4M |
负债/权益比AMSFMLAB
| Q1 26 | — | — | ||
| Q4 25 | — | 0.37× | ||
| Q3 25 | — | 0.39× | ||
| Q2 25 | — | 0.41× | ||
| Q1 25 | — | 0.45× | ||
| Q4 24 | — | 0.47× | ||
| Q3 24 | — | 0.45× | ||
| Q2 24 | — | 0.49× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $18.8M |
| 自由现金流经营现金流 - 资本支出 | — | $18.0M |
| 自由现金流率自由现金流/营收 | — | 27.7% |
| 资本支出强度资本支出/营收 | — | 1.1% |
| 现金转化率经营现金流/净利润 | — | 5.17× |
| 过去12个月自由现金流最近4个季度 | — | $37.9M |
8季度趋势，按日历期对齐
经营现金流AMSFMLAB
| Q1 26 | — | — | ||
| Q4 25 | $11.1M | $18.8M | ||
| Q3 25 | $10.7M | $8.2M | ||
| Q2 25 | $-8.4M | $1.9M | ||
| Q1 25 | $-1.8M | $12.7M | ||
| Q4 24 | $24.2M | $18.1M | ||
| Q3 24 | $8.4M | $5.3M | ||
| Q2 24 | $-2.6M | $10.7M |
自由现金流AMSFMLAB
| Q1 26 | — | — | ||
| Q4 25 | $8.9M | $18.0M | ||
| Q3 25 | $9.8M | $7.1M | ||
| Q2 25 | $-9.5M | $884.0K | ||
| Q1 25 | $-1.8M | $11.9M | ||
| Q4 24 | $23.4M | $17.3M | ||
| Q3 24 | $8.4M | $3.5M | ||
| Q2 24 | $-2.6M | $9.9M |
自由现金流率AMSFMLAB
| Q1 26 | — | — | ||
| Q4 25 | 10.9% | 27.7% | ||
| Q3 25 | 11.9% | 11.7% | ||
| Q2 25 | -11.7% | 1.5% | ||
| Q1 25 | -2.5% | 19.2% | ||
| Q4 24 | 31.5% | 27.6% | ||
| Q3 24 | 10.7% | 6.0% | ||
| Q2 24 | -3.5% | 16.9% |
资本支出强度AMSFMLAB
| Q1 26 | — | — | ||
| Q4 25 | 2.6% | 1.1% | ||
| Q3 25 | 1.1% | 1.8% | ||
| Q2 25 | 1.3% | 1.7% | ||
| Q1 25 | 0.0% | 1.2% | ||
| Q4 24 | 1.1% | 1.3% | ||
| Q3 24 | 0.0% | 3.1% | ||
| Q2 24 | 0.1% | 1.5% |
现金转化率AMSFMLAB
| Q1 26 | — | — | ||
| Q4 25 | 1.06× | 5.17× | ||
| Q3 25 | 0.77× | 3.32× | ||
| Q2 25 | -0.61× | 0.40× | ||
| Q1 25 | -0.20× | — | ||
| Q4 24 | 1.83× | — | ||
| Q3 24 | 0.59× | 1.54× | ||
| Q2 24 | -0.24× | 3.17× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMSF
暂无分部数据
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
